Atai receives 130 million euros
Lisa Marie Münster
| 04.03.2021
With the current financing round, the biotech company Atai is said to be worth 1.7 billion euros. The round was led by German investor Christian Angermayer.
Investment duo Peter Thiel and Christian Angermayer have struck again: €130 million was raised for biotech company Atai Life Sciences via Thiel Capital and Apeiron Investment Group, Angermayer's family office. The venture capitalist Woodline Partners, which specializes in pharmaceutical investments, is a new addition.
Berlin-based start-up Atai Life Sciences is researching the effects of psychedelic substances to combat mental illnesses such as depression or anxiety. The aim is to use the substances commercially as a therapy under medical supervision; Angermayer is one of the world's largest investors in this field.
According to insiders, Atai is valued at 1.7 billion euros, in addition, an IPO on the US tech exchange Nasdaq is planned for the second quarter of 2021, according to the news agency Reuters
. Atai received 100 million euros from investors as recently as autumn 2020.
Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectTake care, give care
Did this news inform or entertain you? Then we would be happy if you tell your network about it.
Share on Linkedin Share on Facebook Share on XingRelated companies
Accelerator
2018
Berlin
ATAI
Global biotech company builder with focus on solutions for mental health disorders.
FYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
